Raising Biomarker Awareness

Dr. Jaspal Singh, MD, medical director for critical care practice and education at Atrium Health discusses a white paper on optimizing molecular testing for lung and bladder cancers. The paper highlighted gaps in molecular testing, emphasizing the need for better specimen management and education. Lung cancer, which kills more people in the U.S. than any other cancer, was particularly noted for its aggressive nature and late diagnosis. Barriers include pragmatic issues, insurance coverage confusion, and outdated clinical practices. The team proposed reflex testing, combining tissue and blood tests upfront, to improve treatment precision and outcomes. Education for both clinicians and patients is crucial to bridge these gaps.

• Dr Singh explains the gap between the availability of testing and its execution, and the implications of the science.
• Patients are often scared and want to start treatment immediately, which can lead to a lack of precise therapy.
• Non-small cell lung cancer has a higher percentage of people getting tested compared to bladder and prostate cancer.
• The field of oncology is evolving rapidly, and many doctors may not keep up with the latest advancements.